How to Protect Your Bones on Mounjaro, Wegovy or Ozempic

Do weight loss injections actually damage your bones? (What the studies really say)

Short answer: bone mineral density can fall modestly during treatment with GLP-1 injections, but the best current evidence suggests this is driven by the rapid weight loss itself rather than a direct toxic effect of the drug. Whenever the body loses a large amount of weight quickly — through dieting, surgery or medication — some bone and muscle is shed alongside the fat. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) appear to follow that same pattern.

The clearest controlled data come from semaglutide. In a 2024 phase 2 randomised trial, 64 adults at increased fracture risk (mostly postmenopausal women, plus a small number of men) received once-weekly semaglutide 1.0 mg or placebo for 52 weeks. The semaglutide group ended with modestly lower bone density at the lumbar spine (estimated treatment difference −0.018 g/cm², p=0.007) and total hip (−0.020 g/cm², p=0.001). Importantly, the change at the femoral neck was not statistically significant (p=0.328), so it is wrong to say "every site" declined. A marker of bone breakdown (P-CTX) rose while a marker of bone formation (P-PINP) did not, and the researchers attributed the loss to the accompanying weight loss — about 6.8 kg more than placebo Hansen et al., eClinicalMedicine, 2024.

Two caveats matter for reading this honestly. First, that trial used semaglutide 1.0 mg — the diabetes dose, not the higher 2.4 mg weight-management (Wegovy) dose. Second, Mounjaro (tirzepatide) does not yet have a comparable trial. The only human bone data in our sources for tirzepatide is a 2025 conference abstract that pooled tirzepatide with semaglutide in a retrospective review of 255 patients — useful as a signal, but not a peer-reviewed, tirzepatide-specific study Liu et al., ENDO 2025 meeting abstract MON-817.

Why does rapid weight loss affect bone density?

Because bone is living tissue that constantly adapts to the load placed on it. When you lose weight rapidly, several things happen at once that signal bone to remodel down:

• Less mechanical loading — a lighter body places less force through the skeleton, so bone is told it needs less of itself.
• Muscle loss — losing lean mass reduces the pull of muscle on bone, one of the key stimuli for bone strength.
• Nutritional gaps — appetite suppression can mean less protein, calcium and vitamin D arriving at the very moment bone needs them.

This is why the size of the bone change tends to track the size of the weight loss. In the retrospective tirzepatide-and-semaglutide review, the fall in total-hip density was correlated with how much weight people lost (Pearson r=0.35, p<0.001) Liu et al., 2025. The reassuring flip side is that bone loss tied to weight loss is largely modifiable — through the load you put on the skeleton and what you feed it.

Who is most at risk of bone loss on a GLP-1?

The groups that show up most clearly in the data are older adults and postmenopausal women. The semaglutide bone trial was run deliberately in adults at increased fracture risk — mostly postmenopausal women Hansen et al., 2024. In the retrospective review, the population was 92% female with a mean age of 68, and 13% (33 of 255) had a new fracture recorded over follow-up Liu et al., 2025.

You have more reason to take active protection — and to know your baseline — if you:

• are postmenopausal or over 40;
• already have low bone density, osteoporosis, or a previous fragility fracture;
• are losing weight very quickly or to a low body weight;
• have other risk factors such as a family history of osteoporosis, long-term steroid use, smoking or heavy alcohol intake.

It is worth holding the counterweight evidence here too. A 2025 real-world cohort of 1,845 people with type 2 diabetes found GLP-1 use associated with a roughly 31% lower risk of an osteoporosis diagnosis (adjusted hazard ratio 0.69) Chen et al., Frontiers in Endocrinology, 2025. That is genuinely reassuring — but it is specific to a type 2 diabetes population, and should not be read as proof that the injections protect bone in people taking them purely for weight loss.

What exercises protect your bones while taking a GLP-1?

The single most encouraging finding in this whole field is that exercise appears to protect bone during GLP-1 weight loss. In a 2024 JAMA Network Open secondary analysis, adults with obesity were split into exercise alone, drug alone, or both. Despite the combination group losing the most weight (about 16.9 kg), adding exercise preserved bone: the drug-alone group lost more density at the hip (−0.026 g/cm²) and spine (−0.020 g/cm²) than the combination group (hip −0.019, spine −0.011), while exercise alone roughly maintained bone (hip −0.013, spine −0.003). For reference, the placebo group's hip change was −0.012 g/cm² Jensen et al., JAMA Network Open, 2024.

One important caveat: that trial used liraglutide 3.0 mg — a related but different GLP-1 medication, not semaglutide or tirzepatide. It points the direction strongly rather than proving it for Mounjaro, Wegovy or Ozempic specifically.

In practice, the UK osteoporosis guideline recommends combining two types of activity, and that maps neatly onto protecting bone during weight loss NOGG 2024 guideline (published 2025):

• Muscle-strengthening (resistance) training — weights, bands or bodyweight, two to three times a week, to load muscle and bone and defend the lean mass you would otherwise lose.
• Weight-bearing activity — walking, stairs, hiking, dancing — to keep mechanical load running through the skeleton.
• Falls-prevention work — the NOGG 2024 guideline highlights programmes of three hours a week or more for those at risk, because most fractures happen in a fall.

Muscle and bone work as a team, so protecting one protects the other — see our guide to the best exercises for bone health for how to structure a week.

Which nutrients matter most — and how much do you actually need?

Three nutrients carry most of the load: calcium provides the raw material, vitamin D lets you absorb it, and protein defends the muscle and collagen scaffold your bones depend on. Appetite suppression on these injections makes it surprisingly easy to fall short of all three.

The UK NOGG 2024 guideline sets clear minimums NOGG 2024 guideline (published 2025):

• Calcium: at least 700 mg a day, preferably from food. Dairy, tinned fish with the bones, fortified plant drinks, and green leafy vegetables (broccoli, cabbage, kale) all count.
• Vitamin D: at least 800 IU (20 micrograms) a day for people with insufficiency or risk factors.
• Lifestyle minimums the guideline also names: keeping alcohol to no more than 2 units a day, and stopping smoking — both protect bone independently.

Protein deserves a special mention on a GLP-1. Because some muscle is lost with any large weight loss, getting enough protein helps you hold on to the lean mass that loads and protects bone. Aim to spread good protein across your meals, even when your appetite is reduced.

One honest limit: calcium and vitamin D help, but they cannot completely prevent weight-loss-related bone change on their own — which is exactly why exercise and monitoring sit alongside them rather than being optional extras. For a deeper look, see our guide to vitamin D, calcium and protein for bone health.

Should you get your bones scanned before or during GLP-1 treatment?

If you are over 40, postmenopausal, or already have low bone density, a baseline scan before or early in treatment is a sensible precaution — because there is currently no routine NHS bone-monitoring programme for people on weight-loss injections. That gap means most people lose bone silently, with no way of knowing until a problem appears.

A baseline scan answers the only question that really matters: is my bone density changing, and do I need to act? Because the changes are gradual, catching them early is precisely when prevention works best — and it lets you measure whether your exercise and nutrition are actually holding the line.

Why a radiation-free REMS scan suits repeat monitoring

Standard DEXA scans use a small dose of X-ray radiation, which makes frequent re-scanning less ideal across a one- or two-year course of treatment. REMS (Radiofrequency Echographic Multi Spectrometry) is radiation-free, so it can be repeated safely to track change over time. A 2025 systematic review of 17 studies (11,664 patients) reported good diagnostic concordance with DXA (around 63.6–90%) and noted REMS is particularly suited to patients needing frequent or serial imaging — which describes monitoring on a weight-loss injection well Icatoiu et al., Diagnostics, 2025.

You can book a screening or read more about our bone health assessment and where we run assessment days across the UK.

When should you speak to a GP or specialist about your bone health?

Talk to your GP or a bone specialist before or early in treatment if you already have osteoporosis, have had a fragility fracture, are postmenopausal, or have other risk factors such as long-term steroid use. A weight-loss injection can still be the right choice for you — the point is to manage the bone side deliberately rather than leave it to chance.

It is worth raising bone health with your prescriber if you:

• have a previous low-trauma fracture or a strong family history of osteoporosis;
• are losing weight very rapidly or notice yourself eating very little;
• have a scan result showing low bone density that you want to monitor over treatment.

None of this is a reason to avoid these medications — for many people the benefits of treating obesity are substantial. It is a reason to go in informed, with a baseline you can measure against. For the wider evidence picture, see our companion guide on whether Ozempic and weight-loss injections cause bone loss.

---

This article is part of our weight-loss medications and bone health series. If you are navigating menopause as well, our menopause and bone health guides cover the overlap — and you can always book a radiation-free bone screening to find out where your bones actually stand.